astrazeneca stock jumped on monday after the british drugmaker reported “groundbreaking” trial results for a new breast cancer drug the pharmaceutical giant said interim analysis of a phase 3 trial showed that its drug enhertu reduced the risk of death or disease progression by 72 compared with an existing treatment—trastuzumab emtansine tdm1